Abstract Body: Objective: To determine the association between intracerebral hemorrhage mortality and statin therapy, aiming to provide effective methods to prevent intracerebral hemorrhage and reduce the mortality rate.

Background: Intracerebral hemorrhage (ICH) poses significant challenges due to its high mortality and disability rates, especially among Asian populations. Contributing factors such as hypocholesterolemia and hypertension amplify the risk of ICH and subsequent hematoma expansion, underscoring the urgent need for effective interventions. Despite the lack of established pharmacological treatments for ICH, statins have emerged as promising candidates for neuroprotection, attributed to their pleiotropic effects beyond lipid-lowering properties.

Methods: This study meticulously conducted a systematic search of various databases until February 2024 to identify relevant literature on statin therapy following ICH. The inclusion criteria encompassed randomized controlled trials (RCTs) and observational cohort studies, ensuring a comprehensive analysis of the available evidence. Data extraction was performed rigorously, involving screening, extraction, and cross-checking by two independent investigators utilizing a predefined table. Quality assessment was carried out using the Newcastle-Ottawa Scale, a recognized tool for evaluating observational studies.

Results:The analysis of 14 studies comprising 86,838 patients revealed a substantial reduction in mortality associated with statin therapy post-ICH, with an odds ratio (OR) of 0.37 and a 95% confidence interval (CI) of 0.25-0.57 (p < 0.00001). However, heterogeneity was observed in studies assessing outcomes such as intraventricular hemorrhage and Glasgow Coma Scale (GCS), indicating variability in populations or methodologies.

Conclusion: One of the significant life-threatening condicions is ICH, and patients are associated with poor prognosis. There is no effective pharmacological treatment to decrease ICH mortality, While statin therapy demonstrates promising potential in mitigating post-ICH mortality, this study underscores the necessity for further research to elucidate optimal treatment duration and address existing heterogeneity. Standardized studies are imperative to inform evidence-based clinical decisions and improve outcomes for individuals afflicted with intracranial hemorrhage.